BIEL Vision Statement
A vision statement helps publicly traded companies, like any other organization, by articulating their long-term goals and aspirations. It serves to inspire employees, guide strategy, and communicate the company’s future impact to investors and stakeholders. For BIEL, a clear Vision Statement would not only strengthen confidence but could propel the PPS toward a billion-dollar valuation (.04), by aligning its strategy with the rapidly growing bioelectronic medicine sector.
Industry Context
Bioelectronic medicine is one of the fastest-growing areas in healthcare, projected to expand at a CAGR of 5.6–9.2% and reach tens of billions of dollars. Growth is fueled by chronic disease prevalence, demand for non-invasive therapies, opioid alternatives, and strong R&D investment.
Future trends point toward closed-loop systems powered by AI and sensors, enabling personalized, real-time treatment by modulating the body’s neural networks.
Policy Alignment: CMS ACCESS Program
On December 4, 2025, the Centers for Medicare & Medicaid Services (CMS) announced the ACCESS program (Advancing Chronic Care with Effective, Scalable Solutions) — a 10-year pilot that reimburses healthcare organizations for telehealth software, wearable devices, and health coaching apps if they improve patient outcomes.
Key highlights:
AI-powered Medicare decisions will approve or deny claims to ensure patients get the care they “need and deserve.”
Upfront payments available for conditions including chronic musculoskeletal pain, depression, diabetes, and hypertension.
Comanagement fees for primary care physicians who refer patients to ACCESS partners.
First-time coverage for nonmedical wearables and health coaching apps.
Praised by major medical groups (AMA, ACC, APA).
This policy shift directly supports BIEL’s FDA-cleared devices (ActiPatch, RecoveryRx), positioning them as reimbursable therapeutic wearables within Medicare’s digital health ecosystem.
Strategic Roadmap for BIEL (ActiPatch & RecoveryRx)
Phase 1: Foundation (0–12 months)
Expand FDA indications (neuropathy, post-surgical recovery).
Launch RCTs in chronic pain, maternal health, recovery.
Develop APIs for integration with Apple Health, Fitbit, hospital EHRs.
Begin pilot collaborations with Electrome for biometric monitoring + therapy bundles.
Phase 2: Market Entry (12–24 months)
Secure CMS reimbursement codes under ACCESS.
Work with private insurers for opioid-alternative programs.
Formalize Electrome collaboration for closed-loop systems.
Launch consumer campaigns positioning ActiPatch as a “smart therapeutic wearable.”
Phase 3: Ecosystem Integration (24–36 months)
Integrate therapy outcomes into AI dashboards for predictive analytics.
Embed ActiPatch/RecoveryRx into diabetes and maternal health ecosystems.
Expand globally, targeting Asia-Pacific and underserved regions.
Phase 4: Leadership Position (36–48 months)
Align with RFK Jr.’s national wearables initiative.
Advocate for inclusion in federal digital health programs.
Diversify into smart patches with embedded sensors, veterinary, and sports medicine.
Pursue strategic acquisition partnerships.
Strategic Takeaway
ACCESS program provides immediate reimbursement pathways for BIEL’s devices in chronic pain, diabetes, and recovery.
Electrome collaboration adds AI-driven monitoring, creating closed-loop therapeutic ecosystems.
RFK Jr.’s wearables initiative amplifies adoption, aligning BIEL with national policy goals.
Bottom Line: With a clear vision, BIEL can transform from a niche pain-relief company into a global leader in therapeutic wearables — supported by CMS reimbursement, AI integration, and federal health initiatives.
A vision statement helps publicly traded companies, like any other organization, by articulating their long-term goals and aspirations. It serves to inspire employees, guide strategy, and communicate the company’s future impact to investors and stakeholders. For BIEL, a clear Vision Statement would not only strengthen confidence but could propel the PPS toward a billion-dollar valuation (.04), by aligning its strategy with the rapidly growing bioelectronic medicine sector.
Industry Context
Bioelectronic medicine is one of the fastest-growing areas in healthcare, projected to expand at a CAGR of 5.6–9.2% and reach tens of billions of dollars. Growth is fueled by chronic disease prevalence, demand for non-invasive therapies, opioid alternatives, and strong R&D investment.
Future trends point toward closed-loop systems powered by AI and sensors, enabling personalized, real-time treatment by modulating the body’s neural networks.
Policy Alignment: CMS ACCESS Program
On December 4, 2025, the Centers for Medicare & Medicaid Services (CMS) announced the ACCESS program (Advancing Chronic Care with Effective, Scalable Solutions) — a 10-year pilot that reimburses healthcare organizations for telehealth software, wearable devices, and health coaching apps if they improve patient outcomes.
Key highlights:
AI-powered Medicare decisions will approve or deny claims to ensure patients get the care they “need and deserve.”
Upfront payments available for conditions including chronic musculoskeletal pain, depression, diabetes, and hypertension.
Comanagement fees for primary care physicians who refer patients to ACCESS partners.
First-time coverage for nonmedical wearables and health coaching apps.
Praised by major medical groups (AMA, ACC, APA).
This policy shift directly supports BIEL’s FDA-cleared devices (ActiPatch, RecoveryRx), positioning them as reimbursable therapeutic wearables within Medicare’s digital health ecosystem.
Strategic Roadmap for BIEL (ActiPatch & RecoveryRx)
Phase 1: Foundation (0–12 months)
Expand FDA indications (neuropathy, post-surgical recovery).
Launch RCTs in chronic pain, maternal health, recovery.
Develop APIs for integration with Apple Health, Fitbit, hospital EHRs.
Begin pilot collaborations with Electrome for biometric monitoring + therapy bundles.
Phase 2: Market Entry (12–24 months)
Secure CMS reimbursement codes under ACCESS.
Work with private insurers for opioid-alternative programs.
Formalize Electrome collaboration for closed-loop systems.
Launch consumer campaigns positioning ActiPatch as a “smart therapeutic wearable.”
Phase 3: Ecosystem Integration (24–36 months)
Integrate therapy outcomes into AI dashboards for predictive analytics.
Embed ActiPatch/RecoveryRx into diabetes and maternal health ecosystems.
Expand globally, targeting Asia-Pacific and underserved regions.
Phase 4: Leadership Position (36–48 months)
Align with RFK Jr.’s national wearables initiative.
Advocate for inclusion in federal digital health programs.
Diversify into smart patches with embedded sensors, veterinary, and sports medicine.
Pursue strategic acquisition partnerships.
Strategic Takeaway
ACCESS program provides immediate reimbursement pathways for BIEL’s devices in chronic pain, diabetes, and recovery.
Electrome collaboration adds AI-driven monitoring, creating closed-loop therapeutic ecosystems.
RFK Jr.’s wearables initiative amplifies adoption, aligning BIEL with national policy goals.
Bottom Line: With a clear vision, BIEL can transform from a niche pain-relief company into a global leader in therapeutic wearables — supported by CMS reimbursement, AI integration, and federal health initiatives.
